Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The current head of Johnson & Johnson's consumer-health division will helm the business after J&J turns it into a stand-alone company.

J&J names executives of planned Tylenol, Band-Aid company

Bristol-Myers

Bristol-Myers Squibb and Johnson & Johnson have a lot to offer investors.

2 No-Brainer Pharma Stocks to Buy Right Now

Johnson & Johnson recently became part of the group that has raised its dividends for six straight decades.

This Dividend King Just Joined an Exclusive Club -- Here's Why the Stock Is a Buy

Johnson & Johnson (NYSE: JNJ) has announced it has appointed Thibaut Mongon as the CEO of the company's new consumer health spin-off. These are the details.

Johnson & Johnson (JNJ) Names Thibaut Mongon As CEO Of Consumer Health Spin-Off

Johnson & Johnson said Wednesday it has named company veteran Thibaut Mongon as chief executive designate of its planned new consumer health company. The company had said in November 2021 that it planned to separate the consumer business into a new company, while keeping its pharmaceutical and medical-device units.

Johnson & Johnson names company veteran Thibaut Mongon as CEO of new consumer health company

Johnson & Johnson on Wednesday appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of next year.

J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business

J&J announced in November that it would sheer off the consumer health business from its faster-growing medical devices and pharmaceutical portfolios.

J&J names Thibaut Mongon, current consumer health leader, as CEO of new spin-off company

The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J. , May 11, 2022 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company.

Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

Fundamental research might seem boring, but it is the only way to find companies that generate real profits and have stocks that carry less risk.

Focus On Fundamentals In Stormy Markets: Johnson & Johnson (JNJ)

J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.

J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk

Apple

Procter & Gamble

Alphabet

Apple, Alphabet, Johnson & Johnson and Procter & Gamble are our 4 blue-chip stocks to buy this month as bulls looks for safe yet solid stocks. The post 4 Blue-Chip Stocks to Buy for May 2022 appeared first on InvestorPlace.

4 Blue-Chip Stocks to Buy for May 2022

Is Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?

Is J&J Stock A Buy After Throwing Off The Covid Vaccine Shackles?

U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson's JNJ, -1.91% COVID-19 vaccine due to a rare but serious risk of blood clots,the Associated Press reported. The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J'svaccine.

Coronavirus tally: FDA limits who can get J&J COVID vaccine over rare blood clot issue

FDA said single-dose shot should be given only to those who request it or cannot receive other vaccines.

J&J's Covid Vaccine Restricted by FDA Over Rare Blood Clot Risk

The restriction, in line with a CDC recommendation, is over a rare but serious blood-clotting risk.

FDA Puts Limits on Johnson & Johnson's COVID Vaccine

Moderna and Pfizer's Covid-19 vaccines are preferable to Johnson & Johnson's vaccine because they have significantly milder side effects, the Food and Drug Administration said.

FDA Limits Use Of Johnson & Johnson Vaccine Due To Blood Clot Risk

Abbott Labs

Where's the safer place to park your money?

Better Dividend King: Johnson & Johnson vs. Abbott Laboratories

Costco

W.W. Grainger

Kinder Morgan

Southern Company

We continuously invest in dividend growth stocks to grow our passive income. Earnings projections are being revised downwards to account for the impact inflation is having on costs and continued supply chain issues.

8 Dividend Increases Expected In May 2022

The company's nearly inflation-proof earnings make it attractive to investors.

Why Johnson & Johnson Stock Held Steady in April

NEW BRUNSWICK, N.J. , May 2, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1 st, at the New York Hilton Midtown in New York.

Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference

Constellation Brands

Target

Despite a tough start to 2022, intelligent investors will follow Warren Buffett's advice and “be greedy when others are fearful” and stay in. The post It Pays to Be Greedy appeared first on InvestorPlace.

It Pays to Be Greedy

Apple, J&J and IBM were the largest companies that announced dividend hikes in the second half of April. While IBM's small increase and J&J mid-single digit increase were as expected, Apple's 4.5% increase was below my expectations.

Apple, J&J, IBM Come Through With Annual Dividend Increases In Second Half Of April

AbbVie

Atmos Energy

Essex Property Trust

Coca-Cola

McDonald's

Exxon Mobil

The writing is on the wall, and veteran investors know it. Any time you have an almost a 1,000 point move in the venerable Dow Jones industrial average and give it all back the next day like we did late last week, it indicates that fund managers are selling every uptick, and savvy hedge fund portfolio managers are trying to clear as much margin debt as possible.

8 Dividend Aristocrat Leaders to Buy Now With the Stock Market Ready to Blow Up

These dividend stocks are breaking out toward new all-time highs.

3 Unstoppable Dow Dividend Kings to Boost Your Passive Income Stream

Adobe

Home Depot

Shopify

Many are quick to call tech stocks overvalued -- but what if the opposite is true?

News for Johnson & Johnson Stock (JNJ)